Carlson Capital Management Upped Its Graco (GGG) Position; Momenta Pharmaceuticals, Inc. (MNTA) Had 5 Analysts Last Week

Graco Inc. (NYSE:GGG) Logo

Among 12 analysts covering Momenta Pharmaceuticals (NASDAQ:MNTA), 5 have Buy rating, 2 Sell and 5 Hold. Therefore 42% are positive. Momenta Pharmaceuticals had 29 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was downgraded by Leerink Swann to “Mkt Perform” on Wednesday, February 22. The stock of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) earned “Hold” rating by Stifel Nicolaus on Tuesday, January 30. On Friday, November 13 the stock rating was initiated by JP Morgan with “Overweight”. The firm earned “Hold” rating on Tuesday, October 31 by Cowen & Co. Barclays Capital maintained the shares of MNTA in report on Wednesday, October 4 with “Equal-Weight” rating. The rating was downgraded by Goldman Sachs to “Neutral” on Thursday, August 6. The stock has “Hold” rating by Maxim Group on Friday, January 8. Stifel Nicolaus maintained Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) on Wednesday, August 2 with “Buy” rating. The rating was maintained by Leerink Swann with “Outperform” on Wednesday, May 4. Barclays Capital maintained it with “Overweight” rating and $20 target in Tuesday, January 31 report. See Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) latest ratings:

22/02/2018 Broker: Stifel Nicolaus Old Rating: Hold New Rating: Buy Upgrade
30/01/2018 Broker: Stifel Nicolaus Rating: Hold New Target: $18.0 Maintain

Carlson Capital Management increased Graco Inc (GGG) stake by 186.72% reported in 2017Q4 SEC filing. Carlson Capital Management acquired 11,685 shares as Graco Inc (GGG)’s stock declined 0.59%. The Carlson Capital Management holds 17,943 shares with $811,000 value, up from 6,258 last quarter. Graco Inc now has $7.65B valuation. The stock decreased 0.11% or $0.05 during the last trading session, reaching $45.61. About 447,820 shares traded. Graco Inc. (NYSE:GGG) has risen 44.03% since May 16, 2017 and is uptrending. It has outperformed by 32.48% the S&P500.

More notable recent Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) news were published by: Nasdaq.com which released: “Momenta Pharmaceuticals Contemplates Its Future” on May 15, 2018, also Nasdaq.com with their article: “Momenta Pharmaceuticals to Webcast Presentation at the Bank of America Merrill Lynch Health Care Conference 2018” published on May 10, 2018, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer’s Trial …” on May 10, 2018. More interesting news about Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) were released by: Nasdaq.com and their article: “Momenta Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update” published on May 08, 2018 as well as Nasdaq.com‘s news article titled: “Report: Developing Opportunities within Interface, Oxford Industries, CVR Energy, Cubic, Momenta Pharmaceuticals …” with publication date: April 30, 2018.

The stock increased 3.09% or $0.65 during the last trading session, reaching $21.7. About 342,552 shares traded. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has risen 23.66% since May 16, 2017 and is uptrending. It has outperformed by 12.11% the S&P500.

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company has market cap of $1.68 billion. The companyÂ’s complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. It currently has negative earnings. The Company’s biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates.

Investors sentiment decreased to 1.45 in Q4 2017. Its down 0.28, from 1.73 in 2017Q3. It is negative, as 19 investors sold Momenta Pharmaceuticals, Inc. shares while 36 reduced holdings. 23 funds opened positions while 57 raised stakes. 71.96 million shares or 2.47% more from 70.23 million shares in 2017Q3 were reported. Tocqueville Asset Ltd Partnership accumulated 963,784 shares. Moreover, Manufacturers Life Insurance The has 0% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Metropolitan Life has 0% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 24,504 shares. Raymond James invested in 0% or 16,086 shares. Meeder Asset Management holds 0% or 697 shares. Primecap Mngmt Ca invested in 2.87 million shares. Jacobs Levy Equity holds 231,862 shares or 0.06% of its portfolio. Sei Invests reported 104 shares stake. Group Inc One Trading L P, Illinois-based fund reported 3,588 shares. Renaissance Technology Llc reported 1.58M shares stake. Tci Wealth Advsrs holds 73 shares or 0% of its portfolio. Oppenheimer Asset Mgmt accumulated 26,658 shares. Credit Suisse Ag has 0% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 95,421 shares. Royal Bancorporation Of Canada reported 28,522 shares. Fmr Lc invested in 0.02% or 11.45M shares.

Since December 13, 2017, it had 0 insider buys, and 20 sales for $4.61 million activity. 493 Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shares with value of $8,918 were sold by Kaundinya Ganesh Venkataraman. WHEELER CRAIG A sold $64,800 worth of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) on Wednesday, February 21. On Monday, February 12 Storer Scott M sold $60,216 worth of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) or 3,972 shares. Shares for $8,516 were sold by Leicher Bruce. Shares for $292,752 were sold by Stoner Elizabeth. KWON YOUNG had sold 14,993 shares worth $326,463.

Among 15 analysts covering Graco Inc (NYSE:GGG), 2 have Buy rating, 0 Sell and 13 Hold. Therefore 13% are positive. Graco Inc has $143.0 highest and $45.0 lowest target. $67.67’s average target is 48.37% above currents $45.61 stock price. Graco Inc had 36 analyst reports since September 15, 2015 according to SRatingsIntel. The stock of Graco Inc. (NYSE:GGG) has “Neutral” rating given on Wednesday, January 31 by B. Riley & Co. The firm has “Hold” rating given on Wednesday, October 11 by RBC Capital Markets. The stock of Graco Inc. (NYSE:GGG) earned “Hold” rating by RBC Capital Markets on Monday, May 1. On Wednesday, February 1 the stock rating was maintained by RBC Capital Markets with “Sector Perform”. The company was maintained on Wednesday, August 16 by Oppenheimer. The stock has “Hold” rating by RBC Capital Markets on Monday, July 10. RBC Capital Markets maintained Graco Inc. (NYSE:GGG) on Tuesday, January 30 with “Hold” rating. SunTrust initiated the shares of GGG in report on Tuesday, November 3 with “Buy” rating. On Thursday, July 27 the stock rating was maintained by RBC Capital Markets with “Hold”. The stock of Graco Inc. (NYSE:GGG) has “Hold” rating given on Wednesday, December 13 by Robert W. Baird.

More news for Graco Inc. (NYSE:GGG) were recently published by: Seekingalpha.com, which released: “Graco Inc. 2018 Q1 – Results – Earnings Call Slides” on April 26, 2018. Seekingalpha.com‘s article titled: “Graco up 5% on Q1 results, raises guidance” and published on April 26, 2018 is yet another important article.

Graco Inc. (NYSE:GGG) Institutional Positions Chart